Hims & Hers launched generic semaglutide on its Canadian telehealth platform on May 21, 2026. The company is using a version produced by Apotex following the expiration of Novo Nordisk’s patent exclusivity. Monthly pricing for the alternative starts at C$149.
Eli Lilly released Phase 3 trial results for its triple-agonist obesity drug, retatrutide. The drug achieved a record-breaking 28.3% weight loss in clinical trials. This performance exceeds the results of Novo Nordisk’s Wegovy.
Novo Nordisk shares fell 2.55% to $43.92 following these developments. Investors are reacting to increased international competition and next-generation clinical rivals.